Capítulo 2. Tratamiento de la Enfermedad de Parkinson

OLANOW CW, WATTS RI, KOLLER,WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines. Neurology. 2001; 56(Suppl 5):S1-S88. v

FOX S, KATZENSCHLAGER R, LIM SY, RAVINA B, SEPPI K, COELHO M, POEWE W, RASCOL O, GOETZ C, SAMPAIO C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson’s Disease. Movement Disorders. 2011; 26(Suppl): S3-S41.

POEWE W. Treatments for Parkinson disease—past achievements and current clinical needs. Neurology. 2009; 72(Suppl 2):S65–S73.

WHEATLEY K, STOWE RL, CLARKE CE, HILLS RK, WILLIAMS AC, GRAY R. Evaluating drug treatments for Parkinson’s disease: how good are the trials?. BMJ. 2002; 324:1508–11.

FERREIRA JJ, KATZENSCHLAGER R, BLOEM B, BONUCCELLI U, BURN D, DEUSCHL G, ET AL. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. European Journal of Neurology. 2013; 20:5–15.

PARKINSON STUDY GROUP. A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients With Parkinson Disease and Motor Fluctuations. The PRESTO Study. Arch Neurol. 2005; 62(2):241-248.

RASCOL O, BROOKS DJ, MELAMED E, OERTEL W, POEWE W, STOCCHI F, TOLOSA E, FOR THE LARGO STUDY GROUP. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005; 365:947–54.

OLANOW CW, STERN MB, SETHI K. The scientific and clinical basis for the treatment of parkinson disease. Neurology. 2009; 72:S1-S136.

SHAPIRA A. Treatmen Options in the Modern Management of Parkinson Disease. Arch Neurol. 2007; 64:1083-1088.

LEES AJ, KATZENSCHLAGER R, HEAD J, BEN-SHLOMO Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology. 2001; 57:1687-94.

COOPER JA, SAGAR HJ, DOHERTY SM, JORDAN N, TIDSWELL P, SULLIVAN EV. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. Brain. 1992; 115:1701-25.

SNOW BJ, MACDONALD L, MCAULEY D, WALLIS W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind placebo-controlled study. Clin Neuropharmacol. 2000; 23:82-5.

RODNITZKY RL, NARAYANAN NS. Amantadine’s role in the treatment of levodopa-induced dyskinesia. Neurology. 2014; 82(4):288-9.

FÉRNANDEZ W, ARANGO G. Movimientos Anormales: temblor esencial y Tratamiento de la Enfermedad de Parkinson. En: Consensos en neurología, guías de práctica clínica. Asociacion Colombiana de Neurología. Exilibris Editores SA. 2001.

FOX SH, LANG AE. Levodopa-related motor complications – phenomenology. Movement Disorders. 2008; 23(Suppl 3):S509-14.

AHLSKOG JE, MUENTER MD. Frecuency of levodopa – related dyskinesias and motor fluctuations as estimated from the cumulative literatura. Movement Disorders. 2001; 16(3):448-458.

QUINN NP. Classification of fluctuations in patients with Parkinson’s disease. Neurology. 1998; 51(Suppl 2):S25-S29.

OBESO JA, RODRIGUEZ-OROZ MC, CHANA P, LERA G, RODRIGUEZ M, OLANOW CW. The evolution and origin of motor complications in Parkinson´s disease. Neurology 2000; 55(Suppl 4):S13-S20; discussion S1-S3.

LEE WY, YOON WT, SHIN HY, JEON SH, RHEE PL. Helicobacter pylori infection and motor fluctuations in patients with Parkinson´s disease. Movement Disorders. 2008; 23(12):1696-16700.

FHAN S. The freezing phenomenon in parkinsonism. Advances in neurology. 1995; 67:53-63.

DEL SORBO F, ALBANESE A. Levodopa-induced dyskinesias and their management. Journal of neurology. 2008; 255(Suppl 4):32-41.

GRACE AA. Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy. Movement Disorders. 2008; 23(Suppl 3):S560-S569.

OKUNMS,TAGLIATIM,POURFARM, ET AL.Managementofreferr eddeepbrainstimu- lation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol. 2005; 62(8):1250-1255.

MORGANTE L, MORGANTE F, MORO E, ET AL. How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? results of a questionnaire. Parkinsonism Relat Disord. 2007; 13(8):528-531.

MORO E, VOLKMANN J, KÖNIG IR, ET AL. Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. Neurology. 2008; 70(14):1186-1191.

LOHMANN E, WELTER ML, FRAIX V, ET AL.French Parkinson’s Disease Genetics study group. Are parkin patients particularly suited for deep-brain stimulation? Mov Disord. 2008; 23(5):740- 743.

SHIH LC, TARSY D. Deep brain stimulation for the treatment of atypical parkinsonism. Mov Disord. 2007; 22(15):2149-2155.

LANG AE, HOUETO JL, KRACK P, ET AL. Deep brain stimulation: preoperative issues. Mov Disord. 2006; 21(suppl 14):S171-S196.

SCHÜPBACH WM, MALTETE D, HOUETO JL, ET AL. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology. 2007; 68(4):267-271

Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006; 21(suppl 14):S290-S304.

BRONSTEIN J, TAGLIATI M, ALTERMAN R, LOZANO A, ET ALS. Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues. Arch Neurol. 2011; 68(2):165-171.

VOON V, KRACK P, LANG AE, ET AL. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease. Brain. 2008; 131(pt 10):2720-2728.

ROSENOW JM, REZAL AR. Surgical Technique and complication avoidance. In: Baltuch GH, Stern MB, eds. Surgical Management of Movement Disorders. Boca Rathon: Taylor & Francis. 2005:45-62.

ANDERSON VC, BURCHIEL KJ, HOGARTH P, FAVRE J, HAMMERSTAD JP. Pallidal vs subthalamic nucleus deep brain Stimulation in Parkinson disease. Arch Neurol. 2005; 62:554-560.

COHEN DS, LUSTGARDTEN JH, MILLER E, KHANDL AG, GOODMAN RR. Effectsof coregistration of MR to CT images on MR sterotactic accuracy. J Neurosurg. 1995; 82:772-779.

KONDZIOLKA D. DEMPSEY PK, LUNSFORD LD, ET AL. A comparasion between magnetic resonance imaging and computed tomography for sterotactic coordinate determination. Neurosurgery. 1992; 30:402-406.

GURIDI J, RODRIGUEZ-OROZ MC, RAMOZ E, LINAZASORO G, OBESO JA. Discrepancia entre la imagen y neurofisiología en estimulación cerebral profunda en el globo pálido medial y en el núcleo subtalámico en la enfermedad de Parkinson. Neurología 2001; 17(4):183-192.

GROSS RE, KRACK P, RODRIGUEZ-OROZ MC, REZAI A, BENAVID AL. Electrophysiological mapping for the implantation of Deep Brain Stimulators for Parkinson´s disease and Tremor. Movement Disorders. 2006; 21(Suppl 14): S259-S283.

VOLKMANN J, HRZOG J, KOPPER F, DEUSCHL G. Introduction to the programming of Deep Brain Stimulators. Movement Disorders. 2002; 17(Suppl 3):S181-S187.

HARIZ MI. Complications of Deep Brain Stimulation surgery. Movement Disorders.2002; 17:S162-S166.

KONDZIOLKA D, WHITING D, GERMANWALA A, OH M. Hardware-related complications after placement of thalamic deep brain stimulator system. Stereotact Funct Neurosurg. 2002; 79:228-233.

BERIC A, KELLY PJ, REZAI A, ET AL. Complications of deep brain stimulation surgery. Stereotact Funct Neurosurg. 2001; 77:73-78.

TERAO T, TAKAHASHI, YOKOSHI F, ET AL. Hemorrhagic complications of stereotactic surgery in patients with movement disorders. J Neurosurg. 2003; 98:1241-1246.

UMEMURA A, JAGGI JL, HURTIG HI, ET AL. Deep Brain stimukation for movement disorders: morbidity and mortality in 109 patients. J Neurosurg. 2003; 98:779-784.

OH MY, ABOSH A, KIM SH, LANG AE, LOZANO AM. Long-term hardware-related complications of deep brain stimulation. Neurosurgery. 2002; 50:1268-1274.

HABERLER C, ALESCH F, MAZAL PR ET AL. No tissue damage by chronic deep brain stimulation in parkinson disease. Ann Neurol. 200; 48:372-376.

FILY F, HAEGELEN C, TATTEVIN P, BUFFET-BATAILLON S, REVEST M, CADY A, MICHELET CH. Deep Brain Stimulation Hardware-Related Infections: A Report of 12 Cases and Review of the Literature. CID. 2011; 52:1020-1023.

LYONS KE, WILKINSON SB, OVERMAN J, ET AL. Surgical and Hardware complications of subthalamic stimulation. A serie of 160 procedures. Neurology. 2004; 63:612-616.